Investigation of the association between serum uric acid levels and HEART risk score in patients with acute coronary syndrome.
Ramin Khameneh BagheriMona Najaf NajafiMostafa AhmadiMohsen SaberiMina MalekiVafa Baradaran RahimiPublished in: Physiological reports (2022)
The association between uric acid (UA) and cardio-metabolic conditions has been recognized for a long time. However, recently, a body of evidence has highlighted the independent role of UA in a series of conditions, including renal and cardiovascular diseases. In this light, data regarding the prognostic role of UA in acute coronary syndrome (ACS) is scarce. A total number of 100 patients, 59 males and 41 females, diagnosed with ACS were recruited in this study. At the time of admission to the hospital, the serum level of UA was measured. In addition, the HEART score was calculated based on each patients' profile. Participants were on average 61.37 ± 12.08 years old. The most prevalent risk factors were hypertension (48%), a history of coronary artery disease (40%), and diabetes mellitus (33%). The average serum level of UA was 5.81 ± 1.81 mg/dl, and the calculated HEART score had a median of six (minimum of two and maximum of ten). A positive yet statistically insignificant correlation was found between the measured UA level and the calculated HEART score (R = 0.375, p = 0.090). However, further studies with larger sample size are required to assess the direct association of UA level with major adverse cardiac events in patients with cardiovascular disease.
Keyphrases
- uric acid
- acute coronary syndrome
- cardiovascular disease
- end stage renal disease
- coronary artery disease
- metabolic syndrome
- heart failure
- ejection fraction
- chronic kidney disease
- risk factors
- newly diagnosed
- percutaneous coronary intervention
- healthcare
- blood pressure
- type diabetes
- prognostic factors
- machine learning
- adipose tissue
- cardiovascular events
- big data
- antiplatelet therapy
- cardiovascular risk factors
- skeletal muscle
- acute care
- adverse drug
- aortic valve
- coronary artery bypass grafting
- transcatheter aortic valve replacement
- case control